Search results

NICE was unable to make a recommendation about the use in the NHS of tenofovir alafenamide for treating chronic hepatitis B because no evidence submission was

Type

Technology appraisal guidance

Published

22 March 2017

NICE was unable to make a recommendation about the use in the NHS of bevacizumab for epidermal growth factor receptor mutation-positive non-small-cell lung

Type

Technology appraisal guidance

Published

22 March 2017

NICE is unable to make a recommendation about the use of ibrutinib with bendamustine and rituximab for relapsed or refractory chronic lymphocytic leukaemia

Type

Technology appraisal guidance

Published

22 March 2017

This guideline covers assessing, diagnosing and managing mental health problems in adults (aged 18 and over) who are in contact with the criminal justice system. It aims to improve mental health and wellbeing in this population by establishing principles for assessment and management, and promoting more coordinated care planning and service organisation across the criminal justice system.

Type

NICE guideline

Published

21 March 2017

Evidence-based recommendations on ustekinumab (Stelara) for treating moderate to severe psoriasis in adults

Type

Technology appraisal guidance

Last updated

03 March 2017

Evidence-based recommendations on ustekinumab (Stelara) for treating active psoriatic arthritis in adults

Type

Technology appraisal guidance

Last updated

03 March 2017

Evidence-based recommendations on everolimus (Afinitor) for advanced renal cell carcinoma (kidney cancer) after previous treatment

Type

Technology appraisal guidance

Published

22 February 2017

Evidence-based recommendations on apremilast (Otezla) for treating active psoriatic arthritis in adults

Type

Technology appraisal guidance

Published

22 February 2017

This guideline covers diagnosing, assessing and managing cerebral palsy in children and young people from birth up to their 25th birthday. It aims to make sure they get the care and treatment they need for the developmental and clinical comorbidities associated with cerebral palsy, so that they can be as active and independent as possible.

Type

NICE guideline

Published

25 January 2017

Evidence-based recommendations on ibrutinib (Imbruvica) for treating chronic lymphocytic leukaemia in adults

Type

Technology appraisal guidance

Published

25 January 2017

Evidence-based recommendations on sofosbuvir–velpatasvir (Epclusa) for treating chronic hepatitis C in adults

Type

Technology appraisal guidance

Published

25 January 2017

Evidence-based recommendations on mepolizumab (Nucala) for treating severe refractory eosinophilic asthma in adults

Type

Technology appraisal guidance

Published

25 January 2017

Evidence-based recommendations on pomalidomide (Imnovid) for multiple myeloma previously treated with lenalidomide and bortezomib in adults

Type

Technology appraisal guidance

Published

11 January 2017

Evidence-based recommendations on pertuzumab (Perjeta) for treating HER2-positive breast cancer that is locally advanced, inflammatory, or early-stage with a

Type

Technology appraisal guidance

Published

21 December 2016

Evidence-based recommendations on dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant/intolerant chronic myeloid leukaemia in adults

Type

Technology appraisal guidance

Published

21 December 2016

Evidence-based recommendations on dasatinib (Sprycel), nilotinib (Tasigna) and imatinib (Glivec) for untreated chronic myeloid leukaemia in adults

Type

Technology appraisal guidance

Published

21 December 2016

Evidence-based recommendations on everolimus (Afinitor) for treating advanced breast cancer in adults after endocrine therapy

Type

Technology appraisal guidance

Published

21 December 2016

Evidence-based recommendations on crizotinib (Xalkori) for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults

Type

Technology appraisal guidance

Published

21 December 2016

Evidence-based recommendations on eribulin (Halaven) for treating locally advanced or metastatic breast cancer after 2 or more types of chemotherapy

Type

Technology appraisal guidance

Published

21 December 2016

Evidence-based recommendations on ticagrelor (Brilique) for preventing atherothrombotic events such as heart attacks or stroke after myocardial infarction (MI)

Type

Technology appraisal guidance

Published

14 December 2016

This guideline covers how to improve services for people aged 14 and above who have been diagnosed as having coexisting severe mental illness and substance misuse. The aim is to provide a range of coordinated services that address people’s wider health and social care needs, as well as other issues such as employment and housing.

Type

NICE guideline

Published

30 November 2016

Evidence-based recommendations on dapagliflozin (Forxiga) in combination therapy for treating type 2 diabetes in adults

Type

Technology appraisal guidance

Last updated

23 November 2016

Evidence-based recommendations on nivolumab (Opdivo) for previously treated advanced renal cell carcinoma in adults

Type

Technology appraisal guidance

Published

23 November 2016

Evidence-based recommendations on dapagliflozin (Forxiga) given with 2 other drugs for treating type 2 diabetes in adults

Type

Technology appraisal guidance

Published

23 November 2016

Evidence-based recommendations on apremilast (Otezla) for treating moderate to severe plaque psoriasis in adults

Type

Technology appraisal guidance

Published

23 November 2016

This guideline covers assessing, diagnosing and managing physical health problems of people in prison. It aims to improve health and wellbeing in the prison population by promoting more coordinated care and more effective approaches to prescribing, dispensing and supervising medicines.

Type

NICE guideline

Published

02 November 2016

Evidence-based recommendations on elbasvir–grazoprevir (Zepatier) for treating genotype 1 or 4 chronic hepatitis C (HCV) in adults

Type

Technology appraisal guidance

Published

26 October 2016

Evidence-based recommendations on cobimetinib (Cotellic) with vemurafenib (Zelboraf) for unresectable or metastatic melanoma in adults with a BRAF V600

Type

Technology appraisal guidance

Published

26 October 2016

Evidence-based recommendations on certolizumab pegol (Cimzia) for treating severe active rheumatoid arthritis in adults who have had a tumour necrosis factor

Type

Technology appraisal guidance

Published

26 October 2016

Evidence-based recommendations on necitumumab (Portrazza) for treating locally advanced or metastatic epidermal growth factor receptor (EGFR)-expressing

Type

Technology appraisal guidance

Published

28 September 2016

Evidence-based recommendations on talimogene laherparepvec (Imlygic) for treating unresectable metastatic melanoma in adults

Type

Technology appraisal guidance

Published

28 September 2016

Evidence-based recommendations on aflibercept (Eylea) for treating visual impairment caused by macular oedema after branch retinal vein occlusion

Type

Technology appraisal guidance

Published

28 September 2016

Evidence-based recommendations on pegaspargase (Oncaspar) for treating acute lymphoblastic leukaemia

Type

Technology appraisal guidance

Published

28 September 2016

Evidence-based recommendations on secukinumab (Cosentyx) for treating active ankylosing spondylitis that has not responded well enough to conventional therapy

Type

Technology appraisal guidance

Published

28 September 2016

Evidence-based recommendations on radium-223 dichloride (Xofigo) for treating hormone-relapsed prostate cancer with bone metastases

Type

Technology appraisal guidance

Published

28 September 2016

Evidence-based recommendations on crizotinib (Xalkori) for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (NSCLC) in adults

Type

Technology appraisal guidance

Published

28 September 2016

This guideline covers children and young people who display harmful sexual behaviour, including those on remand or serving community or custodial sentences. It aims to ensure these problems don’t escalate and possibly lead to them being charged with a sexual offence. It also aims to ensure no-one is unnecessarily referred to specialist services.

Type

NICE guideline

Published

20 September 2016

This guideline covers preventing, assessing and managing mental health problems in people with learning disabilities in all settings (including health, social care, education, and forensic and criminal justice). It aims to improve assessment and support for mental health conditions, and help people with learning disabilities and their families and carers to be involved in their care.

Type

NICE guideline

Published

14 September 2016

This guideline covers the period before, during and after a person is admitted to, and discharged from, a mental health hospital. It aims to help people who use mental health services, and their families and carers, to have a better experience of transition by improving the way it’s planned and carried out.

Type

NICE guideline

Published

30 August 2016

Evidence-based recommendations on ramucirumab (Cyramza) for treating previously treated locally advanced or metastatic non-small-cell lung cancer

Type

Technology appraisal guidance

Published

24 August 2016

Evidence-based recommendations on degarelix (Firmagon) for advanced hormone-dependent prostate cancer in adults with spinal metastases

Type

Technology appraisal guidance

Published

24 August 2016

Evidence-based recommendations on trifluridine–tipiracil (Lonsurf) for previously treated metastatic colorectal cancer in adults

Type

Technology appraisal guidance

Published

24 August 2016

Evidence-based recommendations on bosutinib (Bosulif) for previously treated chronic myeloid leukaemia in adults

Type

Technology appraisal guidance

Published

24 August 2016

Evidence-based recommendations on pemetrexed (Alimta) for locally advanced or metastatic non-squamous non-small-cell lung cancer in adults who have had

Type

Technology appraisal guidance

Published

24 August 2016

Evidence-based recommendations on cabazitaxel (Jevtana) for prostate cancer that has come back after it was treated with docetaxel

Type

Technology appraisal guidance

Last updated

24 August 2016

Evidence-based recommendations on abiraterone (Zytiga) for castration-resistant metastatic prostate cancer in adults who have had previous treatment with a

Type

Technology appraisal guidance

Last updated

27 July 2016

Evidence-based recommendations on abiraterone (Zytiga) for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated in adults

Type

Technology appraisal guidance

Last updated

27 July 2016

Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for treating advanced (unresectable or metastatic) melanoma in adults

Type

Technology appraisal guidance

Published

27 July 2016

Evidence-based recommendations on lumacaftor–ivacaftor (Orkambi) for treating cystic fibrosis in people 12 years and older who are homozygous for the F508del

Type

Technology appraisal guidance

Published

27 July 2016

Evidence-based recommendations on azacitidine (Vidaza) for treating acute myeloid leukaemia (AML) with more than 30% bone marrow blasts

Type

Technology appraisal guidance

Published

27 July 2016